NCT05074992View on ClinicalTrials.gov

A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

May 2, 2023

Study Completion Date

May 2, 2023

Conditions
Glioblastoma
Interventions
DRUG

Ipilimumab

Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

Trial Locations (4)

Unknown

Aberdeen Royal Infirmary, Aberdeen

St Bartholomew's Hospital, London

University College London Hospital, London

Queen's Hospital, Romford

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University College, London

OTHER

NCT05074992 - A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma | Biotech Hunter | Biotech Hunter